

TAF5L antibody - middle region

Rabbit Polyclonal Antibody

Catalog # AI10381

Product Information

Application	WB
Primary Accession	O75529
Other Accession	NM_014409 , NP_055224
Reactivity	Human, Mouse, Rat, Zebrafish, Pig, Dog, Bovine
Predicted	Human, Mouse, Rat, Zebrafish, Pig, Chicken, Dog, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	66155

Additional Information

Gene ID	27097
Alias Symbol	PAF65B
Other Names	TAF5-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 5L, PCAF-associated factor 65 beta, PAF65-beta, TAF5L, PAF65B
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-TAF5L antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	TAF5L antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures.


Protein Information

Name	TAF5L (HGNC:17304)
Synonyms	PAF65B
Function	Functions as a component of the PCAF complex. The PCAF complex is capable of efficiently acetylating histones in a nucleosomal context. The PCAF complex could be considered as the human version of the yeast SAGA complex (Probable). With TAF6L, acts as an epigenetic regulator essential for somatic reprogramming. Regulates target genes through H3K9ac deposition and MYC recruitment which trigger MYC regulatory network to orchestrate gene expression programs to control embryonic stem cell state (By similarity).

References

Ravnskjaer,K., (2007) EMBO J. 26 (12), 2880-2889 Reconstitution and Storage:For short term use, store at 2-8C up to 1 week. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles.

Images



WB Suggested Anti-TAF5L Antibody Titration: .2-1 ug/ml
ELISA Titer: 1:625
Positive Control: Human Stomach

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.